Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood?

Surgery Today ◽  
2016 ◽  
Vol 46 (12) ◽  
pp. 1402-1409 ◽  
Author(s):  
Noriyoshi Sawabata ◽  
Soichiro Funaki ◽  
Takeru Hyakutake ◽  
Yasushi Shintani ◽  
Ayako Fujiwara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Cells ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Small Cell ◽  
Surgical Patients ◽  
Small Cell Lung ◽  
Surgical Manipulation

scholarly journals Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer

PLoS ONE ◽  
2017 ◽  
Vol 12 (7) ◽  
pp. e0181211 ◽  
Author(s):  
Ippokratis Messaritakis ◽  
Eleni Politaki ◽  
Athanasios Kotsakis ◽  
Eleftheria-Kleio Dermitzaki ◽  
Filippos Koinis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Peripheral Blood ◽  
Small Cell ◽  
Phenotypic Characterization ◽  
Small Cell Lung

scholarly journals Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3394
Author(s):  
Hsin-Lun Lee ◽  
Jeng-Fong Chiou ◽  
Peng-Yuan Wang ◽  
Long-Sheng Lu ◽  
Chia-Ning Shen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Drug Sensitivity ◽  
Ex Vivo ◽  
Small Cell ◽  
Small Cell Lung ◽  
Blood Samples

Small cell lung cancer (SCLC) represents one of the most aggressive malignancies among cancer types. Not only tumor sample availability is limited, but also the ability for tumor cells to rapidly acquire drug resistance are the rate-limiting bottlenecks for overall survival in current clinical settings. A liquid biopsy capable of capturing and enriching circulating tumor cells (CTCs), together with the possibility of drug screening, is a promising solution. Here, we illustrate the development of a highly efficient ex vivo CTC expansion system based on binary colloidal crystals substrate. Clinical samples were enrolled from 22 patients with SCLC in the study. The CTCs were enriched and expanded from the collected peripheral blood samples. Expanded cells were analyzed for protein expression and observed for drug sensitivity with the use of immunofluorescence and ATP titer evaluation, respectively. Successful CTC spheroid proliferation was established after 4 weeks within 82% of all the collected peripheral blood samples from enrolled patients. Upon immunofluorescence analysis, the enriched cells showed positive markers for EpCAM, TTF-1, synaptophysin and negative for CD45. Additionally, the expanded CTCs demonstrated marked heterogeneity in the expression of E-cadherin and N-cadherin. In a preliminary case series, the drug sensitivity of patient-derived CTC to cisplatin and etoposide was studied to see the correlation with the corresponding therapeutic outcome. In conclusion, our study demonstrates that it is possible to efficiently expand CTCs from SCLC within a clinically relevant time frame; the biomarker information generated from enriched CTCs can assist the selection of effective drugs and improve disease outcome.

TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients

Lung Cancer ◽  
2011 ◽  
Vol 71 (2) ◽  
pp. 209-216 ◽  
Author(s):  
Sun Och Yoon ◽  
Young Tae Kim ◽  
Kyeong Cheon Jung ◽  
Yoon Kyung Jeon ◽  
Baek-Hui Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Poor Prognosis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Correlation of circulating tumor cells with myeloid-derived suppressive cells in the peripheral blood of patients with advanced small cell lung cancer

2016 ◽  
Vol 27 ◽  
pp. vi19
Author(s):  
I. Messaritakis ◽  
A. Koutoulaki ◽  
D. Aggouraki ◽  
E.K. Vetsika ◽  
E. Politaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Peripheral Blood ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Circulating tumor cells as a prognostic factor in patients with small cell lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7592-7592 ◽  
Author(s):  
Satoshi Igawa ◽  
Jiichiro Sasaki ◽  
Noriyuki Masuda
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Peripheral Blood ◽  
Fluorescent Protein ◽  
Small Cell ◽  
Small Cell Lung

7592 Background: Research on the detection of circulating tumor cells (CTCs) in peripheral blood is currently an important field of research. The aim of this study was to evaluate a new method of detecting CTCs in the peripheral blood of small cell lung cancer (SCLC) patients by using the telomerase-specific replication-selective adenovirus OBP-401. Methods: We prospectively enrolled 30 consecutive newly diagnosed SCLC patients who were being started on chemotherapy or chemoradiotherapy as the subjects of this study. We collected peripheral blood specimens from the SCLC patients and detected viable CTCs in them after incubation with a telomerase-specific, replication-selective, oncolytic adenoviral agent carrying the green fluorescent protein (GFP) gene. We also investigated whether the CTC count per 7.5 ml of peripheral venous blood was associated with the outcome of SCLC. Results: CTCs were detected in 96% of the patients (29 of the 30 patients). The group of 22 patients with a CTC count of < 2 before treatment (baseline) had a significantly longer median survival time than the group of 8 patients with a CTC count of ≥ 2 before treatment (14.8 months and 3.9 months, respectively, P = 0.001). The results of a multivariate analysis showed that the baseline CTC count was an independent prognostic factor for survival (hazard ratio = 5.11, P = 0.038). Conclusions: CTCs in the peripheral blood of SCLC patients can be detected by the OBP-401assay, and based on the results of this study the CTC count before treatment appears to be a strong prognostic factor.

Sign in / Sign up

Export Citation Format

Share Document